Idera Pharmaceuticals Completes Enrollment In ILLUMINATE-204 Trial Of The Combination Of Tilsotolimod And Ipilimumab For Unresectable Or Metastatic Melanoma Following Failure Of PD-1 Inhibitor Treatment
Benzinga Newsdesk